JP2025185043A5 - - Google Patents
Info
- Publication number
- JP2025185043A5 JP2025185043A5 JP2025165723A JP2025165723A JP2025185043A5 JP 2025185043 A5 JP2025185043 A5 JP 2025185043A5 JP 2025165723 A JP2025165723 A JP 2025165723A JP 2025165723 A JP2025165723 A JP 2025165723A JP 2025185043 A5 JP2025185043 A5 JP 2025185043A5
- Authority
- JP
- Japan
- Prior art keywords
- hap
- cancer
- patient
- antibody
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662369691P | 2016-08-01 | 2016-08-01 | |
| US62/369,691 | 2016-08-01 | ||
| PCT/US2017/044002 WO2018026606A1 (en) | 2016-08-01 | 2017-07-26 | Administration of hypoxia activated prodrugs in combination with immune modulatory agents for treating cancer |
| JP2019506400A JP2019527236A (ja) | 2016-08-01 | 2017-07-26 | 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与 |
| JP2022144394A JP2022189827A (ja) | 2016-08-01 | 2022-09-12 | 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022144394A Division JP2022189827A (ja) | 2016-08-01 | 2022-09-12 | 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025185043A JP2025185043A (ja) | 2025-12-18 |
| JP2025185043A5 true JP2025185043A5 (cg-RX-API-DMAC10.html) | 2026-03-06 |
Family
ID=61073118
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019506400A Pending JP2019527236A (ja) | 2016-08-01 | 2017-07-26 | 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与 |
| JP2022144394A Pending JP2022189827A (ja) | 2016-08-01 | 2022-09-12 | 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与 |
| JP2025165723A Pending JP2025185043A (ja) | 2016-08-01 | 2025-10-01 | 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019506400A Pending JP2019527236A (ja) | 2016-08-01 | 2017-07-26 | 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与 |
| JP2022144394A Pending JP2022189827A (ja) | 2016-08-01 | 2022-09-12 | 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20210369746A1 (cg-RX-API-DMAC10.html) |
| EP (2) | EP4549467A3 (cg-RX-API-DMAC10.html) |
| JP (3) | JP2019527236A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2018026606A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109999183B (zh) * | 2019-04-15 | 2021-03-09 | 中国科学技术大学 | 一种含有乏氧激活前药的纳米簇化酶及其制备方法和应用 |
| WO2023025291A1 (zh) | 2021-08-27 | 2023-03-02 | 深圳艾欣达伟医药科技有限公司 | 冻干制剂溶液及冻干制剂、方法和用途 |
| JP7762796B2 (ja) | 2021-08-27 | 2025-10-30 | アセンタウィッツ ファーマシューティカルズ リミテッド | Ｐａｒｐ阻害剤に耐性のある患者のｔｈ－３０２による治療 |
| US20250186468A1 (en) | 2022-03-15 | 2025-06-12 | Ascentawits Pharmaceuticals, Ltd. | Method for treating patient with brca-mutated cancer |
| EP4509127A4 (en) | 2022-04-15 | 2026-07-15 | Ascentawits Pharmaceuticals Ltd | CANCER TREATMENT METHOD USING TH-302 ALONE OR IN COMBINATION WITH A PARP INHIBITOR |
| EP4529926A4 (en) | 2022-05-23 | 2026-07-01 | Ascentawits Pharmaceuticals Ltd | CANCER TREATMENT METHOD BY COMBINATION OF AN ALKYLATING AGENT PRODRUGATION AND A CELL CYCLE INHIBITOR |
| CN119894521A (zh) | 2022-09-22 | 2025-04-25 | 深圳艾欣达伟医药科技有限公司 | 乏氧激活的化合物在制备治疗癌症患者的药物中的用途 |
| EP4674418A1 (en) | 2023-02-27 | 2026-01-07 | Ascentawits Pharmaceuticals, Ltd. | Solution, freeze-dried formulation, freeze-dried formulation unit package, injection, and injection preparation method |
| EP4755396A1 (en) | 2023-07-28 | 2026-06-10 | Ascentawits Pharmaceuticals, Ltd. | Treatment of p53 gene mutation or defect negative cancer and tumor patients |
| CN121985960A (zh) | 2023-10-18 | 2026-05-05 | 深圳艾欣达伟医药科技有限公司 | 治疗p53基因突变阴性、kras基因突变阳性、brca突变阳性患者 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| ZA200507752B (en) | 2003-03-28 | 2007-01-31 | Threshold Pharmaceuticals Inc | Compositions and methods for treating cancer |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| ZA200800314B (en) | 2005-06-29 | 2009-09-30 | Threshold Pharmaceuticals Inc | Phosphoramidate alkylator prodrugs |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| US8552048B2 (en) | 2006-12-26 | 2013-10-08 | Threshold Pharmaceuticals, Inc. | Phosphoramidate alkylator prodrugs for the treatment of cancer |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| EA201500417A1 (ru) | 2008-08-25 | 2015-11-30 | Эмплиммьюн, Инк. | Композиции антагонистов pd-1 и способы применения |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| WO2010048330A1 (en) * | 2008-10-21 | 2010-04-29 | Threshold Pharmaceuticals, Inc. | Treatment of cancer using hypoxia activated prodrugs |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| US8962808B2 (en) * | 2010-05-05 | 2015-02-24 | The Research Foundation For The State University Of New York | EGFR-related polypeptides and methods of use |
| AU2011276590A1 (en) * | 2010-06-28 | 2013-01-31 | Threshold Pharmaceuticals, Inc. | Treatment of blood cancer |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| WO2013116385A1 (en) * | 2012-01-31 | 2013-08-08 | Threshold Pharmaceuticals, Inc. | Predictive biomarker for hypoxia-activated prodrug therapy |
| PL3099717T3 (pl) * | 2014-01-31 | 2019-10-31 | Novartis Ag | Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie |
| WO2015191568A2 (en) * | 2014-06-09 | 2015-12-17 | Biomed Valley Discoveries, Inc. | Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature |
| KR20170066546A (ko) * | 2014-10-03 | 2017-06-14 | 노파르티스 아게 | 조합 요법 |
-
2017
- 2017-07-26 US US16/322,467 patent/US20210369746A1/en active Pending
- 2017-07-26 EP EP25151614.2A patent/EP4549467A3/en active Pending
- 2017-07-26 JP JP2019506400A patent/JP2019527236A/ja active Pending
- 2017-07-26 WO PCT/US2017/044002 patent/WO2018026606A1/en not_active Ceased
- 2017-07-26 EP EP17837425.2A patent/EP3490548A4/en not_active Withdrawn
-
2022
- 2022-09-12 JP JP2022144394A patent/JP2022189827A/ja active Pending
-
2025
- 2025-10-01 JP JP2025165723A patent/JP2025185043A/ja active Pending